Biosciences – Page 2

Coherus BioSciences Completes Strategic Shift with $483M Sale of Last Biosimilar Asset

8 months ago talkbio0Tagged Biosciences, Biosimilars, Biotechnology, Coherus, Drug Industry, strategic pivot

Coherus BioSciences, biosimilars, strategic pivot, pharmaceutical industry, biotechnology

Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million

8 months ago talkbio0Tagged Biosciences, Coherus, Dosage Forms, immuno-oncology, Intas, pegfilgrastim-cbqv, Udenyca

Coherus BioSciences, Udenyca, Intas Pharmaceuticals, pegfilgrastim-cbqv, immuno-oncology, pharmaceutical deal

Coherus Resumes Biosimilar Supply Following Temporary Disruption; Novavax Terminates COVID-19 Vaccine Deal with UK

9 months ago talkbio0Tagged Biosciences, Biosimilar Supply, Coherus, COVID19 (disease), Novavax, Supply chain issues, Udenyca, UK, Vaccines

Coherus BioSciences, Biosimilar supply, UDENYCA, Supply chain issues, Novavax, COVID-19 vaccine deal, UK

Jade Biosciences and Aerovate Therapeutics Announce Strategic Merger to Advance Autoimmune Disease Therapies

9 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Biotechnology, IGA Glomerulonephritis, paragon, reverse merger

Reverse merger, Jade Biosciences, Aerovate Therapeutics, Paragon Therapeutics, Autoimmune diseases, JADE-001, IgA nephropathy (IgAN), Biotechnology

GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager

9 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Chimagen, Lupus Vulgaris, pharmaceutical deals, SmithKline Beecham, T-Lymphocyte

GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals

Ono Pharmaceutical Partners with LigaChem Biosciences for ADC Research and Development

10 months ago talkbio0Tagged Antibody-Drug Conjugates, Biosciences, ConjuAll ADC, Dosage Forms, LCB97, LigaChem, Malignant Neoplasms, Solid Neoplasm, Solid Tumors

Ono Pharmaceutical, LigaChem Biosciences, Antibody-Drug Conjugate (ADC), LCB97, ConjuAll ADC platform, Solid Tumors, Cancer Treatment

IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce

10 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Changing, Immunoglobulin M, imvotamab, Leadership, strategic pivot, T cell-engaging IgM antibodies

IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644

IGM Biosciences Shifts Focus to Autoimmune Diseases Amid Leadership Changes

10 months ago talkbio0Tagged Arthritis, Autoimmune Diseases, Biosciences, Biotechnology, C-suite exits, Immunoglobulin M, Immunology

IGM Biosciences, autoimmune diseases, C-suite exits, biotechnology, immunology, arthritis, lupus

Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption

10 months ago talkbio0Tagged Biosciences, Biosimilars, Cancer Therapeutic Procedure, Coherus, Disruption, Neulasta, pegfilgrastim, Pharmaceutical Supply Chain, Udenyca, White Blood Cell Count procedure

UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.

Biotech IPO Market Sees Rare Upsurge with Triple Listing Success

10 months ago talkbio0Tagged Bicara Therapeutics, Biosciences, biotech, Drug Industry, Flux, IPO, Market, MBX, Stock Surge, Tripleheader, Zenas BioPharma

Biotech IPO, Market Flux, Tripleheader, Bicara Therapeutics, Zenas BioPharma, MBX Biosciences, Stock Surge, Pharmaceutical Industry